Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Rhea-AI Summary

Jupiter Neurosciences (NASDAQ:JUNS) closed a registered direct offering of 7,142,858 common shares, raising approximately $2.0 million in gross proceeds. The company indicates the capital extends cash runway for its Parkinson’s program, supports debt reduction, and funds its Phase 2a RESET trial of JOTROL in Parkinson’s disease.

Preclinical data showed statistically significant neuroprotective effects that supported an IND granted in November 2025.

Positive

• Raised approximately $2.0 million via registered direct equity offering
• Sale of 7,142,858 shares extends cash runway for Parkinson’s program
• Company reports meaningful debt reduction improving shareholder equity position
• Funding supports Phase 2a RESET trial of JOTROL in Parkinson’s disease
• IND for JOTROL granted in November 2025 based on supportive data

Negative

• Issuance of 7,142,858 new shares results in shareholder dilution

News Market Reaction – JUNS

-12.19%

25 alerts

-12.19% Session close to close

+19.2% Peak Tracked

-11.5% Trough Tracked

$9.82M Market Cap

0.4x Rel. Volume

In the May 22 session, JUNS declined 12.19%, reflecting a significant negative market reaction. Argus tracked a peak move of +19.2% during that session. Argus tracked a trough of -11.5% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -12.2% in the session following this news. The decline reflects market sensitivity...

Analysis

The stock dropped -12.2% in the session following this news. The decline reflects market sensitivity to dilution from the $2.0 million registered direct offering, even though management highlighted cash runway extension for the Parkinson’s Phase 2a trial. Unlike the prior offering-pricing release that saw a 10.25% gain, this closing announcement met heavy selling on elevated volume. Continued use of the $100,000,000 S-3 shelf and equity funding could remain an overhang if not matched by clinical or deal milestones.

Key Figures

Registered direct proceeds: $2.0 million Shares issued: 7,142,858 shares Trial phase: Phase 2a +4 more

7 metrics

Registered direct proceeds $2.0 million Gross proceeds from offering described in this release

Shares issued 7,142,858 shares Common stock sold in registered direct offering

Trial phase Phase 2a RESET study in Parkinson’s disease

Trial design Randomized, double-blind, placebo-controlled RESET Phase 2a Parkinson’s trial design

ClinicalTrials.gov ID NCT07592767 RESET Parkinson’s disease study identifier

Neuroprotective effects Statistically significant Preclinical model data for JOTROL motor function endpoints

IND grant date November 2025 IND granted supporting RESET Parkinson’s trial

Previous Offering Reports

1 past event · Latest: May 20 (Negative)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
May 20	Registered direct pricing	Negative	+10.3%	Priced $2.0M registered direct offering of 7,142,858 common shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited offering history shows the prior pricing announcement saw a positive price reaction, contrasting with today’s sharp selloff on closing.

Recent Company History

Over recent months, Jupiter Neurosciences has relied on capital markets while advancing its JOTROL™ and Parkinson’s programs. On May 20, 2026, the company priced a registered direct offering of 7,142,858 shares for roughly $2.0 million, which was followed by a 10.25% gain. That financing came alongside a significant PharmAla ALA-002 term sheet. Today’s news formalizes closing of the same $2.0 million raise, extending cash runway but drawing a markedly negative market response.

Key Terms

registered direct offering, securities purchase agreements, prospectus supplement, multi-center, +3 more

7 terms

registered direct offering financial

"announced the closing of its registered direct offering, pursuant to the securities"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

securities purchase agreements financial

"registered direct offering, pursuant to the securities purchase agreements with certain"

A securities purchase agreement is a legal contract that spells out the terms when a company sells stocks, bonds, or other investment instruments to buyers. It lays out price, how many securities change hands, any promises or protections for each side, and when the sale is completed—like a detailed sales contract for investments. Investors care because it determines ownership stakes, potential dilution, rights attached to the securities, and conditions that affect the company’s future value.

prospectus supplement regulatory

"A prospectus supplement describing the terms of the proposed registered direct"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

multi-center medical

"The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a"

Multi-center describes a study, clinical trial, or project carried out at several separate hospitals, clinics, or research sites rather than at a single location. For investors, multi-center work generally means results are gathered from a broader set of patients and conditions, making findings more reliable and faster to enroll, but also more costly and complex to coordinate—like testing a product in many stores to see how it performs across different neighborhoods.

randomized medical

"The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position 

Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering").

“Yesterday's capital raise helps the Company prepare for key milestones anticipated in the next year,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “We were able to significantly reduce our debt, which improves our balance sheet; and with this capital in hand, we can comfortably execute on the Parkinson’s Phase 2a trial and work towards the consummation of the transaction with PharmALA (ALA-002- MDMA). With a cleaner capital structure of the company and additional cash in hand, we believe that we are well positioned for future financing opportunities.”

A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at dbccapitalmarkets@dboralcapital.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Clinical Trial Details

Jupiter’s RESET (RESvEraTrol in Parkinson’s Disease) is active on www.clinicaltrials.gov, details here:

Study Details | NCT07592767 | RESvEraTrol in Parkinson's Disease (RESET) | ClinicalTrials.gov. The trial is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study designed to evaluate the JOTROL^™ in Parkinson’s Disease. In a well-established model of the human disease, JOTROL demonstrated statistically significant neuroprotective effects including rotarod performance and grip strength, indicating preservation of motor function. These data supported the IND granted to the Company in November 2025.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL^™ -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia^™, a consumer longevity supplement. Most recent, the acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed on April 1, 2026. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact

Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com

Media Contact

Josh Birch, Media Relations Manager
KNB Communications
JBirch@KNBComm.com

FAQ

What did Jupiter Neurosciences (NASDAQ:JUNS) announce about its $2.0 million offering on May 21, 2026?

Jupiter Neurosciences closed a registered direct offering raising approximately $2.0 million in gross proceeds. According to Jupiter Neurosciences, the financing involved 7,142,858 common shares and is intended to extend cash runway, reduce debt, and support its Parkinson’s disease development plans.

How will the May 2026 JUNS registered direct offering impact existing shareholders?

The offering adds new capital but increases the company’s share count, creating dilution for existing holders. According to Jupiter Neurosciences, proceeds help reduce debt and finance the Phase 2a Parkinson’s RESET trial, which may strengthen the balance sheet and support future financing options.

How will Jupiter Neurosciences use proceeds from the $2.0 million JUNS stock sale?

Proceeds are planned to extend cash runway, reduce debt, and fund Parkinson’s development. According to Jupiter Neurosciences, the capital supports execution of the Phase 2a RESET trial of JOTROL in Parkinson’s disease and prepares for milestones expected over the next year.

What is Jupiter Neurosciences’ RESET Phase 2a trial in Parkinson’s disease (JUNS)?

RESET is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial of JOTROL in Parkinson’s disease. According to Jupiter Neurosciences, the study evaluates JOTROL’s effects, building on preclinical data that showed statistically significant neuroprotective benefits and supported IND clearance in November 2025.

What preclinical data support JOTROL for Parkinson’s disease at Jupiter Neurosciences?

JOTROL showed statistically significant neuroprotective effects in a well-established human disease model. According to Jupiter Neurosciences, benefits included improved rotarod performance and grip strength, suggesting preserved motor function and providing the basis for the IND granted in November 2025.

Where can investors find official documents for the Jupiter Neurosciences (JUNS) offering?

Details are available in a prospectus supplement filed with the SEC for the registered direct offering. According to Jupiter Neurosciences, investors can also request the prospectus materials from D. Boral Capital, the placement agent, using the contact information disclosed in the offering announcement.